FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158156749> ?p ?o ?g. }

• W2158156749 endingPage "928" @default.
• W2158156749 startingPage "918" @default.
• W2158156749 abstract "Mutations that disrupt the open reading frame and prevent full translation of DMD, the gene that encodes dystrophin, underlie the fatal X-linked disease Duchenne muscular dystrophy. Oligonucleotides targeted to splicing elements (splice switching oligonucleotides) in DMD pre-mRNA can lead to exon skipping, restoration of the open reading frame, and the production of functional dystrophin in vitro and in vivo, which could benefit patients with this disorder.We did a single-blind, placebo-controlled, dose-escalation study in patients with DMD recruited nationally, to assess the safety and biochemical efficacy of an intramuscular morpholino splice-switching oligonucleotide (AVI-4658) that skips exon 51 in dystrophin mRNA. Seven patients with Duchenne muscular dystrophy with deletions in the open reading frame of DMD that are responsive to exon 51 skipping were selected on the basis of the preservation of their extensor digitorum brevis (EDB) muscle seen on MRI and the response of cultured fibroblasts from a skin biopsy to AVI-4658. AVI-4658 was injected into the EDB muscle; the contralateral muscle received saline. Muscles were biopsied between 3 and 4 weeks after injection. The primary endpoint was the safety of AVI-4658 and the secondary endpoint was its biochemical efficacy. This trial is registered, number NCT00159250.Two patients received 0.09 mg AVI-4658 in 900 microL (0.9%) saline and five patients received 0.9 mg AVI-4658 in 900 microL saline. No adverse events related to AVI-4658 administration were reported. Intramuscular injection of the higher-dose of AVI-4658 resulted in increased dystrophin expression in all treated EDB muscles, although the results of the immunostaining of EDB-treated muscle for dystrophin were not uniform. In the areas of the immunostained sections that were adjacent to the needle track through which AVI-4658 was given, 44-79% of myofibres had increased expression of dystrophin. In randomly chosen sections of treated EDB muscles, the mean intensity of dystrophin staining ranged from 22% to 32% of the mean intensity of dystrophin in healthy control muscles (mean 26.4%), and the mean intensity was 17% (range 11-21%) greater than the intensity in the contralateral saline-treated muscle (one-sample paired t test p=0.002). In the dystrophin-positive fibres, the intensity of dystrophin staining was up to 42% of that in healthy muscle. We showed expression of dystrophin at the expected molecular weight in the AVI-4658-treated muscle by immunoblot.Intramuscular AVI-4658 was safe and induced the expression of dystrophin locally within treated muscles. This proof-of-concept study has led to an ongoing systemic clinical trial of AVI-4658 in patients with DMD.UK Department of Health." @default.
• W2158156749 created "2016-06-24" @default.
• W2158156749 creator A5001672241 @default.
• W2158156749 creator A5009302202 @default.
• W2158156749 creator A5012227405 @default.
• W2158156749 creator A5014695659 @default.
• W2158156749 creator A5018973798 @default.
• W2158156749 creator A5021085969 @default.
• W2158156749 creator A5021347280 @default.
• W2158156749 creator A5023248855 @default.
• W2158156749 creator A5025842975 @default.
• W2158156749 creator A5037732169 @default.
• W2158156749 creator A5046261021 @default.
• W2158156749 creator A5047889091 @default.
• W2158156749 creator A5048288125 @default.
• W2158156749 creator A5051000919 @default.
• W2158156749 creator A5054367024 @default.
• W2158156749 creator A5062861137 @default.
• W2158156749 creator A5064381774 @default.
• W2158156749 creator A5076364419 @default.
• W2158156749 creator A5082377236 @default.
• W2158156749 creator A5083335373 @default.
• W2158156749 creator A5084668009 @default.
• W2158156749 creator A5085249811 @default.
• W2158156749 creator A5087993434 @default.
• W2158156749 creator A5089234882 @default.
• W2158156749 creator A5089279578 @default.
• W2158156749 date "2009-10-01" @default.
• W2158156749 modified "2023-10-16" @default.
• W2158156749 title "Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study" @default.
• W2158156749 cites W1963677157 @default.
• W2158156749 cites W1963948212 @default.
• W2158156749 cites W1969582765 @default.
• W2158156749 cites W1975074465 @default.
• W2158156749 cites W1977695847 @default.
• W2158156749 cites W2003066928 @default.
• W2158156749 cites W2010757394 @default.
• W2158156749 cites W2018862827 @default.
• W2158156749 cites W2022243113 @default.
• W2158156749 cites W2022736892 @default.
• W2158156749 cites W2036948921 @default.
• W2158156749 cites W2044962040 @default.
• W2158156749 cites W2044964290 @default.
• W2158156749 cites W2048680477 @default.
• W2158156749 cites W2054819498 @default.
• W2158156749 cites W2058060911 @default.
• W2158156749 cites W2062442451 @default.
• W2158156749 cites W2066180106 @default.
• W2158156749 cites W2066950610 @default.
• W2158156749 cites W2089229823 @default.
• W2158156749 cites W2091798878 @default.
• W2158156749 cites W2094796370 @default.
• W2158156749 cites W2098051622 @default.
• W2158156749 cites W2109889650 @default.
• W2158156749 cites W2110154453 @default.
• W2158156749 cites W2131960572 @default.
• W2158156749 cites W2147724465 @default.
• W2158156749 cites W2149543855 @default.
• W2158156749 cites W2151501906 @default.
• W2158156749 cites W2152060821 @default.
• W2158156749 cites W2157593661 @default.
• W2158156749 cites W2172085519 @default.
• W2158156749 cites W3094222424 @default.
• W2158156749 cites W4255797162 @default.
• W2158156749 doi "https://doi.org/10.1016/s1474-4422(09)70211-x" @default.
• W2158156749 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2755039" @default.
• W2158156749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19713152" @default.
• W2158156749 hasPublicationYear "2009" @default.
• W2158156749 type Work @default.
• W2158156749 sameAs 2158156749 @default.
• W2158156749 citedByCount "600" @default.
• W2158156749 countsByYear W21581567492012 @default.
• W2158156749 countsByYear W21581567492013 @default.
• W2158156749 countsByYear W21581567492014 @default.
• W2158156749 countsByYear W21581567492015 @default.
• W2158156749 countsByYear W21581567492016 @default.
• W2158156749 countsByYear W21581567492017 @default.
• W2158156749 countsByYear W21581567492018 @default.
• W2158156749 countsByYear W21581567492019 @default.
• W2158156749 countsByYear W21581567492020 @default.
• W2158156749 countsByYear W21581567492021 @default.
• W2158156749 countsByYear W21581567492022 @default.
• W2158156749 countsByYear W21581567492023 @default.
• W2158156749 crossrefType "journal-article" @default.
• W2158156749 hasAuthorship W2158156749A5001672241 @default.
• W2158156749 hasAuthorship W2158156749A5009302202 @default.
• W2158156749 hasAuthorship W2158156749A5012227405 @default.
• W2158156749 hasAuthorship W2158156749A5014695659 @default.
• W2158156749 hasAuthorship W2158156749A5018973798 @default.
• W2158156749 hasAuthorship W2158156749A5021085969 @default.
• W2158156749 hasAuthorship W2158156749A5021347280 @default.
• W2158156749 hasAuthorship W2158156749A5023248855 @default.
• W2158156749 hasAuthorship W2158156749A5025842975 @default.
• W2158156749 hasAuthorship W2158156749A5037732169 @default.
• W2158156749 hasAuthorship W2158156749A5046261021 @default.
• W2158156749 hasAuthorship W2158156749A5047889091 @default.
• W2158156749 hasAuthorship W2158156749A5048288125 @default.
• W2158156749 hasAuthorship W2158156749A5051000919 @default.

• next